Evidence map›Paper›PMID 30277112›Full record

ArticleLeukemia & lymphoma2019

A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Sarah A Buckley, Mary-Elizabeth Percival, Megan Othus, Anna B Halpern, Emily M Huebner, Pamela S Becker, Carole Shaw, Mazyar Shadman, Roland B Walter, Elihu H Estey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sarah A Buckleya Hematology/Oncology Fellowship Program , University of Washington , Seattle , WA , USA.
Mary-Elizabeth Percivalb Department of Medicine , University of Washington , Seattle , WA , USA.ORCID 0000-0002-7016-951X
Megan Othusd Public Health Sciences Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
Anna B Halpernb Department of Medicine , University of Washington , Seattle , WA , USA.
Emily M Huebnerc Clinical Research Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
Pamela S Beckerb Department of Medicine , University of Washington , Seattle , WA , USA.
Carole Shawc Clinical Research Division , Fred Hutchinson Cancer Research Center , Seattle , WA , USA.
Mazyar Shadmanb Department of Medicine , University of Washington , Seattle , WA , USA.
Roland B Walterb Department of Medicine , University of Washington , Seattle , WA , USA.
Elihu H Esteyb Department of Medicine , University of Washington , Seattle , WA , USA.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
NCI NIH HHS P30 CA015704NHLBI NIH HHS T32 HL007093
6 · The paper itself

Abstract

Patients with newly diagnosed (ND) and relapsed/refractory (RR) acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS, ≥10% blasts) often receive intensive chemotherapy at diagnosis and relapse. We retrospectively identified 365 patients and categorized the reasons for receiving treatment off study (medical, logistical, or unclear). The pretreatment characteristics of the on and off study groups were similar. Rates of the complete remission (CR) without measurable residual disease were significantly higher for ND patients treated on versus off study (61% versus 35%), but CR rates and survival were low for all RR patients regardless of study assignment. The subset of ND patients treated off study for medical reasons had significantly decreased overall survival and relapse-free survival. Standard, stringent study eligibility criteria may delineate a population of ND, but not RR, patients with improved outcomes with intensive induction chemotherapy.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyFemaleHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyelodysplastic SyndromesOdds RatioPrognosisProportional Hazards ModelsRemission InductionTreatment OutcomeAMLclinical trialsinduction chemotherapyMDSon study

Identifiers

PMID30277112
PMCPMC6445790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.